Skip to content

The development of a new post-stroke neuroinflammation monitoring software based on multimodal magnetic resonance

The development of a new post-stroke neuroinflammation monitoring software based on multimodal magnetic resonance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109208
Enrollment
Unknown
Registered
2025-09-15
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Sponsors

The First Affiliated Hospital of Chengdu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with ischemic stroke: (1)Diffusion-weighted magnetic resonance imaging (DWI) confirmed ischemic stroke; (2) The occurrence of stroke is less than 1 day; (3) The volume of ischemic lesions is greater than 8 cm^3; (4) No history of neurological or mental disorders. 2.Healthy subjects: Age (+/-5 years) of ischemic stroke patients matched by gender (1) No history of neurological or mental disorders; (2) The score of the mental state examination is greater than 27 points; (3) Be 18 years old or above; (4) No contraindications for MRI; (5) No psychotropic or stimulant drugs have been used.

Exclusion criteria

Exclusion criteria: 1. Under 18 years old; 2. Contraindications for MRI; 3. Life-threatening conditions occurred within 6 months of follow-up.

Design outcomes

Primary

MeasureTime frame
Cranial 3T MRI indicators;Blood inflammatory markers;

Secondary

MeasureTime frame
National Institutes of Health Stroke Scale(NIHSS) Score;Barthel Index;Modified Rankin Scale Score;

Countries

China

Contacts

Public ContactLan Wen

The First Affiliated Hospital of Chengdu Medical College

L_wen1225@163.com+86 189 0820 7080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026